Psoriasis: An up date;Le psoriasis: Actualités

Tunisie Medicale

Volumn 81, Issue 6, 2003, Pages 363-367

  Kharfi, Monia ^a   Zghal, Mohamed ^a   Kamoun, Mohamed Ridha ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Epidemiology; Pathogeny; Psoriasis; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ASCOMYCIN; CALCIPOTRIOL; CAPSAICIN; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOSPORIN; DITHRANOL; KERATOLYTIC AGENT; LIPOXYGENASE INHIBITOR; MACROLIDE; METHOTREXATE; PROTEIN KINASE INHIBITOR; RETINOID; TAZAROTENE;

CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GEL; HEREDITY; HUMAN; NEPHROTOXICITY; PATHOGENESIS; PHOTOTHERAPY; PREVALENCE; PSORIASIS; PSYCHOLOGICAL ASPECT; PUVA; RADIOTHERAPY; REVIEW; RISK FACTOR; ULTRAVIOLET B RADIATION;

HUMANS; PSORIASIS;

EID: 0141522574     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Farber EM, Nall ML. The natural history of psoriasis in 5600 patients. Dermatologica 1974;148:1-18
2. henseler T. The genetics of psoriasis. J Am Acad Dermatol 1997;37:S1-S11
3. Swanbecck G, Inerot A, Martinsson T and all. Genetic conselling in psoriasis. Br j Dermatol 1997;137:939-42
4. Asahina A, Akasaki S, Nakagawa H and all. Specific nucleotide sequence of HLA-C is strongly associated with psorasis. J Invest Dermatol 1991;97:524-28
5. Schimt Egenolf M, Eiermann H, Boehncke WH and all. Familial juvenile onset psoriasisis associated with the human leukocyte antigen (HLA) class I sideof the extended haplotype. J Invest Dermatol 1996;106:711-14
6. Hardas BD, Zhao X, Zhang J. assignement of psoriasis to human chromosomal band 1q21. J Invest dermatol 1996;106:753-58
7. Matthews D, Fry L, Powels A and all. Evidence that a locus for familial psoriasis maps to chromosome 4q. nat Genet 1996;14:231-33
8. Tomfohrde J, Silverman A, barnes R and all. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-45
9. Guilhou JJ. Psoriasis: diagnostic et étiopathogénie. Encycl Méd Chir, Dermatologie 1998,98-190-A-10
10. Daniel F. Que reste-t-il des réducteurs en 1998? Objectif Peau 1998;6:303-308
11. Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Exp Opin Invest Drugs 1998;7:77-84
12. Katz HI. Combined topical calcipotriene ointment 0′005% and various systemic therapies in the tritment of plaque type psoriasis vulgaris. J Am Acad Dermatol 1997;37(suppl):S26-S68
13. Kragballe k. treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992;27:1001-1008
14. Lebwohl M. Tropical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997;37(suppl):S55-S58
15. Ortonne JP. Psoriasis: nouvelle modalité thérapeutique par le calcipotriol plus le dipropionate de bétasone. Nouv Dermatol 1994;13:746-51
16. Berbis, Hesse S, privat Y. rétinoides. Encycl méd Chir dermatologie 12-902-A-10,1993:1-11
17. Roenigk HH, Auerbach R, Maibach H and all. Methotrexate in psoriasis: consensus conference. J Am Acad 1998;38:478-85
18. Grossman RM, Chevret S, Abi-Rached JJ and all. Long term safety of ciclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-29
19. Lebwohl M, Ellis C, Gottlieb A and all. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad dermatol 1998;39 464-75
20. Coven TR, Burack LH, Guilleaudeau P, Keogh M and all. Narrowband UV6Bproduces superior clinical and histological resolution of moderate-to-severe psoriasis in patients compared with broadband UV6B. arch Dermatol 1997;133:1514-22
21. Picot E, Picot-Debeze MC, Meunier L and all. La photothérapie UVB à spectre étroit (lampes Philips TL01) dans le traitement du psoriasis. Ann Dermatol Venereol 1992;119:639-42
22. Stern RS, Nichols KT, Vâkevâ LH and all. Malignant melanoma in patients treated for psoriasis with methoxalen(psoralen) and ultraviolet A radiation(PUVA). N Engl J Med 1997;336:1041-44
23. Stern RS, Vâkevâ LH. Non cutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 1997;108:897-900